ARGENX SE |
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 343.1 EUR | +3.72% |
|
-6.72% | -0.17% |
Presenter SpeechBeth DelGiacco (Executives)Good morning, and thank you to everyone for joining...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
argenx SE is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx SE aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx SE is evaluating efgartigimod in multiple serious autoimmune diseases, and cusatuzumab in hematological cancers in collaboration with Janssen. argenx SE is also advancing several earlier stage experimental medicines within its therapeutic franchises. argenx SE has offices in Belgium, the United States, and Japan.
Calendar
25/07/2024
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
330.8
EUR
Average target price
432.9
EUR
Spread / Average Target
+30.86%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -0.17% | 21.25B | |
| +5.73% | 111B | |
| +11.65% | 106B | |
| -12.61% | 22.24B | |
| -4.97% | 18.97B | |
| -35.21% | 18.52B | |
| -11.19% | 16.81B | |
| +37.84% | 12.54B | |
| -25.04% | 8.09B | |
| +297.61% | 7.99B |
- Stock Market
- Equities
- ARGX Stock
- News argenx SE
- Transcript : argenx SE - Special Call
